Navigation Links
Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery
Date:4/9/2008

ucts that improve their daily lives and perform essential tasks, such as changing their hearing aid battery."

The Arthritis Foundation commendation comes on the heels of a new online hearing health campaign from Duracell launched at the AARP convention in December 2007. The EasyTab "We Hear You" campaign was created as more mature adults turn to the Internet to seek information about their health. The Duracell Web site now offers a place to learn more about hearing health and testing as well as finding a local hearing specialist. For more information, visit http://www.duracelleasytab.com .

"Duracell has a long history of developing products that help make everyday life simpler," said Rachel Calomeni, brand manager, North America, Duracell. "Our Duracell EasyTab battery is a great example of a product designed specifically with the consumer in mind. Recognition by the Arthritis Foundation is an important commendation because it speaks directly to EasyTab's ability to meet the needs of those who rely on our product every day."

Duracell EasyTab now lasts up to 15 percent longer(2), making it the longest lasting Duracell hearing aid battery to date. Available in size 10, 13, 312, and 675, Duracell EasyTab will power all conventional and digital hearing aids in the market including CIC, ITC, ITE and BTE styles. Available in 12-packs, Duracell EasyTab is sold at mass, drug, grocery and specialty stores nationwide. New packaging, including the new ease-of-use seal, will arrive on store shelves in this month. The suggested retail price for Duracell EasyTab hearing aid batteries ranges from $9.49 to $15.99.

About Duracell

Part of The Procter & Gamble Company (NYSE: PG
'/>"/>

SOURCE Procter & Gamble
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Physical activity is natural pain reliever for arthritis
2. New Rheumatoid Arthritis Drug Works for Adults, Children
3. ACCU-CHEK(R) Aviva System Receives Arthritis Foundations Ease-of-Use Commendation
4. Vegan diet promotes atheroprotective antibodies in patients with rheumatoid arthritis
5. Gender bias may affect care of people with osteoarthritis, study finds
6. Gender Bias at Play in Treatment of Knee Osteoarthritis
7. In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market
8. Rheumatoid Arthritis Drugs May Lower Heart Attack, Stroke Risk
9. Study of 137 Meniscus Transplant Procedures in Patients with Arthritis is Presented to the Meniscus Transplantation Study Group at the American Academy of Orthopaedic Surgeons Annual Meeting
10. Misdiagnosis of rheumatoid arthritis
11. Common Rheumatoid Arthritis Drug Wont Raise Blood Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 2Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 3Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 4Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 3Health News:Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals 2Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2Health News:Informed-Choice Reinforces Need to Test Supplements for Inadvertent Contamination After Recent NFL Players' Positive Tests 2Health News:Pharmasset to Webcast an Investor Event from the AASLD Meeting 2Health News:Pharmasset to Webcast an Investor Event from the AASLD Meeting 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2